Document is current
Any future updates will be listed below
-
Authors
Dupuy, Maryne
Gueguinou, Maxime https://orcid.org/0000-0002-5793-2082
Postec, Anaïs https://orcid.org/0009-0001-1197-9838
Brion, Régis
Tesfaye, Robel
Mullard, Mathilde
Regnier, Laura
Amiaud, Jérôme
Hubsch, Clémence
Potier-Cartereau, Marie
Chantôme, Aurélie
Brounais-Le Royer, Bénédicte https://orcid.org/0000-0002-4556-9853
Baud’huin, Marc
Georges, Steven
Lamoureux, François
Ory, Benjamin
Entz-Werlé, Natacha
Delattre, Olivier
Rédini, Françoise
Vandier, Christophe
Verrecchia, Franck https://orcid.org/0000-0003-4920-2554
-
Funding
Funding for this research was provided by:
Institut National Du Cancer (2018-151)
Ligue Contre le Cancer
- License Information
-
More Information
Article History
Received: 26 April 2024
Revised: 11 October 2024
Accepted: 15 October 2024
First Online: 1 November 2024
Competing interests
: The authors declare no competing interests.
: All methods used were performed in accordance with the relevant guidelines and regulations. 18 ES diagnostic tumors collected retrospectively in University Hospitals of Strasbourg between 2005 and 2022 were used. Those patients were treated in or according to the past Euro-E.W.I.N.G.99 and EURO EWING 2012 protocols. The research protocol was validated by the local institutional ethics committee at University Hospitals of Strasbourg for human tissue experiments and a CNIL declaration 1970 390 v0 was obtained. All patients and their parents gave their written informed consent.
